Enzo Biochem Current Ratio 2010-2023 | ENZ
Enzo Biochem current ratio from 2010 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Enzo Biochem Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2023-01-31 |
$0.04B |
$0.03B |
1.13 |
| 2022-10-31 |
$0.05B |
$0.02B |
1.84 |
| 2022-07-31 |
$0.05B |
$0.03B |
2.21 |
| 2022-04-30 |
$0.06B |
$0.03B |
2.52 |
| 2022-01-31 |
$0.07B |
$0.03B |
2.55 |
| 2021-10-31 |
$0.07B |
$0.02B |
2.85 |
| 2021-07-31 |
$0.07B |
$0.03B |
2.71 |
| 2021-04-30 |
$0.07B |
$0.03B |
2.44 |
| 2021-01-31 |
$0.07B |
$0.03B |
2.33 |
| 2020-10-31 |
$0.07B |
$0.03B |
2.09 |
| 2020-07-31 |
$0.07B |
$0.03B |
2.10 |
| 2020-04-30 |
$0.07B |
$0.03B |
2.27 |
| 2020-01-31 |
$0.07B |
$0.02B |
3.07 |
| 2019-10-31 |
$0.08B |
$0.02B |
3.36 |
| 2019-07-31 |
$0.08B |
$0.02B |
5.09 |
| 2019-04-30 |
$0.09B |
$0.02B |
5.61 |
| 2019-01-31 |
$0.06B |
$0.02B |
3.84 |
| 2018-10-31 |
$0.08B |
$0.02B |
4.15 |
| 2018-07-31 |
$0.08B |
$0.02B |
4.12 |
| 2018-04-30 |
$0.09B |
$0.02B |
4.63 |
| 2018-01-31 |
$0.09B |
$0.02B |
4.51 |
| 2017-10-31 |
$0.09B |
$0.02B |
4.66 |
| 2017-07-31 |
$0.09B |
$0.02B |
5.00 |
| 2017-04-30 |
$0.09B |
$0.02B |
5.16 |
| 2017-01-31 |
$0.09B |
$0.02B |
4.95 |
| 2016-10-31 |
$0.09B |
$0.02B |
4.35 |
| 2016-07-31 |
$0.09B |
$0.02B |
4.44 |
| 2016-04-30 |
$0.06B |
$0.02B |
2.55 |
| 2016-01-31 |
$0.06B |
$0.03B |
2.41 |
| 2015-10-31 |
$0.05B |
$0.03B |
2.05 |
| 2015-07-31 |
$0.05B |
$0.02B |
1.94 |
| 2015-04-30 |
$0.04B |
$0.02B |
1.60 |
| 2015-01-31 |
$0.04B |
$0.02B |
1.63 |
| 2014-10-31 |
$0.04B |
$0.03B |
1.62 |
| 2014-07-31 |
$0.04B |
$0.03B |
1.63 |
| 2014-04-30 |
$0.04B |
$0.02B |
1.73 |
| 2014-01-31 |
$0.03B |
$0.02B |
1.35 |
| 2013-10-31 |
$0.03B |
$0.02B |
1.34 |
| 2013-07-31 |
$0.03B |
$0.02B |
1.37 |
| 2013-04-30 |
$0.03B |
$0.02B |
1.46 |
| 2013-01-31 |
$0.03B |
$0.02B |
1.67 |
| 2012-10-31 |
$0.04B |
$0.02B |
1.93 |
| 2012-07-31 |
$0.04B |
$0.02B |
2.13 |
| 2012-04-30 |
$0.04B |
$0.02B |
2.50 |
| 2012-01-31 |
$0.04B |
$0.02B |
2.56 |
| 2011-10-31 |
$0.05B |
$0.02B |
2.71 |
| 2011-07-31 |
$0.05B |
$0.02B |
2.90 |
| 2011-04-30 |
$0.05B |
$0.02B |
3.35 |
| 2011-01-31 |
$0.05B |
$0.02B |
3.22 |
| 2010-10-31 |
$0.06B |
$0.02B |
3.66 |
| 2010-07-31 |
$0.06B |
$0.02B |
3.71 |
| 2010-04-30 |
$0.06B |
$0.01B |
4.78 |
| 2010-01-31 |
$0.07B |
$0.02B |
3.54 |
| 2009-10-31 |
$0.07B |
$0.01B |
5.47 |
| 2009-07-31 |
$0.07B |
$0.01B |
5.34 |
| 2009-04-30 |
$0.08B |
$0.02B |
5.05 |
| 2009-01-31 |
$0.09B |
$0.01B |
6.54 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.110B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
